COMMUNIQUÉS West-GlobeNewswire

TRU NIAGEN® PRO to be Featured at the North American Menopause Society (NAMS) Annual Meeting
03/10/2018
Women’s health practitioners now have access to TRU NIAGEN® PRO for aging patients LOS ANGELES, Oct. 03, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it will highlight its new TRU NIAGEN [...]
BrainStorm Highlights Translational Data and Presentations Supporting NUROWN® Technology Platform as a Best-In-Class Strategy in ALS
03/10/2018
NurOwn® to be Featured at NEALS and Cell & Gene Meeting on the Mesa Conferences NEW YORK and PETACH TIKVAH, Israel, Oct. 03, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading [...]
Wright Medical Group N.V. to Host Third Quarter 2018 Earnings Conference Call
03/10/2018
Wednesday, November 7, 2018, at 3:30 p.m. Central / 4:30 p.m. Eastern AMSTERDAM, The Netherlands, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ: WMGI) today announced that it will host a conference [...]
Adherium Announces Participation in SmartAirLA Effort to Combat Asthma in Los Angeles with Support from Blue Shield of California Foundation
03/10/2018
The Program Aims In Part to Develop Better Models for Expanding Data-Based Medication Adherence SAN MATEO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), a leading digital health platform for medication [...]
Horizon Discovery enters into license agreement with Cytovance Biologics for HD-BIOP3 Suspension adapted GS null CHO K1 cells
03/10/2018
OKLAHOMA CITY, Okla., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Cytovance® Biologics, Inc. signed a non-exclusive license with Horizon Discovery for the use of their HD-BIOP3 Suspension adapted GS null CHO K1 cells. The Horizon [...]
Motif Bio Presents New Iclaprim Data at IDWeek
03/10/2018
Iclaprim safety and efficacy in patients with wound infections in REVIVE Phase 3 trials NEW YORK, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company [...]
Rule 2.9 Announcement
03/10/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 3 October 2018 [...]
PCI Biotech: Last day of subscription period
03/10/2018
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER [...]
Director/PDMR Shareholding
03/10/2018
DXS INTERNATIONAL PLC Director Dealing The Board of DXS International plc (the “Company”), the NEX quoted clinical decision support developer and supplier of clinical decision support systems is pleased to confirm that [...]
Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma
03/10/2018
Overall response rate data from the (RXE 1 ) Phase II study conducted in the US and Sweden met its primary end points and treatment with Doxophos Vet was generally well tolerated. Oasmia’s assessment is that the [...]
Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2018
03/10/2018
LYON, France, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – 30 septembre 2018
03/10/2018
LYON, France, 03 oct. 2018 (GLOBE NEWSWIRE) -- Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Lyon - France Places de cotation : Euronext Paris de Euronext (Compartiment B - Code ISIN : [...]
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
03/10/2018
Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to partner with like-minded innovators [...]
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)
03/10/2018
Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment Nolasiban safety profile not different from placebo in IMPLANT 2 European MAA submission confirmed to be targeted [...]
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million
03/10/2018
LONDON and CARLSBAD, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel [...]
Telix Pharmaceuticals and Cardinal Health Enter into Distribution Agreement for Prostate Cancer Imaging
03/10/2018
INDIANAPOLIS and COLUMBUS, Ohio, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals (US) Inc. (“Telix USA”), a subsidiary of Telix Pharmaceuticals Limited (ASX:TLX), a clinical-stage biopharmaceutical company [...]
Pain Therapeutics Announces Investor Call to Provide Strategic Update
03/10/2018
Call to be Held on Thursday, October 4th, 10:00 AM Eastern Time AUSTIN, Texas, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that it will host a [...]
Dr. Brian Buinewicz Introduces EMSCULPT® to the Long Island Area
03/10/2018
Now, patients can simultaneously build muscle and burn fat for outstanding cosmetic results DOYLESTOWN, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Dr. Brian Buinewicz of Buinewicz Plastic Surgery has been offering patients [...]
Paratek Announces FDA Approval of NUZYRA™ (Omadacycline)
03/10/2018
– Modernized Tetracycline for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) specifically designed to overcome tetracycline resistance – – First and [...]

Pages